APP and Alzheimer disease: Importantly, we discovered that miR-650 can regulate APOE, PSEN1, and CDK5 expression levels in vitro, and we went on to determine that miR-650 could also regulate CDK5 levels in vivo using APP/PSEN1 mice, a conventional model for AD.